Abstract: Objective:To evaluate the clinical efficacy and safety of hyperthermic intraperitoneal chemotherapy，HIPEC in the treatment of gastric cancer with peritoneal carcinomatosis，GCPC.Methods:The clinical data of 67 patients with GCPC who were treated by surgery and confirmed by pathology were retrospectively analyzed.Among them，46 patients undergo HIPEC treatment，the other 21 patients refuse HIPEC treatment.Treatmentrelated complications and postoperative survival data were compared to analyze the factors involved in the prognosis of GCPC patients.Results:There was no significant difference with respect to treatmentrelated serious adverse event，SAE.Patients who received CRS CCR（0～1）（n=24）and HIPEC（n=15）at the same time had a median OS of 14 months，while those who receive CRS alone（n=9）had a median OS of 6 months（P=0.012）.Multivariate analysis suggested that early HIPEC treatment and regular postoperative chemotherapy bring survival benefit for GCPC patients who underwent CRS CCR（0～1），the elevation of serum CA724 were independent risk factor to postoperative survival time of GCPC.Conclusion:For patients with peritoneal metastasis of gastric cancer who achieve complete tumor cell extinction visible to the naked eye，the treatment strategy of CRS+HIPEC will not increase the occurrence of treatation-related complications，and at the same time can prolong the survival of patients.

Key words: hyperthermic intraperitoneal chemotherapy, gastric cancer, peritoneal metastasis, cytoreduction, safety and efficacy